Interleukin (IL) are group of cytokines that are synthesized by lymphocytes, monocytes, macrophages, and other cells. They regulate cell growth, cell differentiation, and cell motility. Fifteen different types of interleukin are present in body. Interleukin inhibitors are immunosuppressive agents that inhibit the action of interleukins. Interleukin inhibitors are used in various conditions including asthma, ankylosing spondylitis, eczema, gout, arthritis (psoriatic and rheumatoid), psoriasis, and systematic sclerosis. Asthma is a chronic and long-term inflammatory disease of the lungs characterized by bronchospasm and airway obstruction. Ankylosing spondylitis is a type of arthritis that affects the spine. It affects about 0.1% to 0.5% of the adult population and can occur at any age. Eczema is a condition where patches of the skin become inflamed, itchy, red, cracked, and rough. It affects 31.6% of people in the U.S. Gout is a common and complex form of arthritis, characterized by severe joint pain. Psoriasis is non-contagious, chronic skin condition characterized by thickened and scaling skin. Systematic sclerosis is a connective tissue disease characterized by atrophy of the skin, vasomotor disturbance, and fibrosis.
Increase in the prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma is a major factor fueling the global interleukin inhibitors market. In addition to this, increase in FDA approvals for novel drugs and therapies for chronic inflammatory disease treatment is further boosting the market. For instance, in 2017, Dupixent monoclonal antibody that targets the interleukin 4 became the first biologic approved for atopic dermatitis. Moreover, the presence of a strong product pipeline and rise in awareness among people regarding chronic inflammatory diseases and their treatment in emerging economies are projected to propel the market in the near future. However, side effects and high cost associated with biological therapy are likely to hamper the global interleukin inhibitors market in next few years.
The global interleukin inhibitors market can be segmented based on disease condition, distribution channel, and region. Based on disease condition, the global interleukin inhibitors market can be categorized into asthma, ankylosing spondylitis, eczema, gout, arthritis (psoriatic and rheumatoid), psoriasis, systematic sclerosis, and others. In terms of distribution channel, the global market can be categorized into hospital pharmacies, online pharmacies, retail pharmacies, clinics, and research institutes.
In terms of region, the global interleukin inhibitors market can be divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to hold a prominent share of the global market, due to rise in the patient pool suffering from psoriasis, arthritis, asthma, and other chronic inflammatory diseases. The presence of well-established drugs makers in North America is further expected to boost the market in the region. Additionally, according to the International Federation of Psoriasis Associations (IFPA), there are about 150,000 new cases of psoriasis every year in the U.S. According to a Centers for Disease Control and Prevention (CDC) report, in 2016, about 26,515 people lived with asthma in the U.S. Europe currently holds a strong position in the global interleukin inhibitors market. However, demand for interleukin inhibitors in the region is likely to decline due to intense competition among key players in the market in Europe. The market in Asia Pacific and Latin America is anticipated to expand at a rapid pace over the next few years due to rise in awareness regarding chronic inflammatory diseases, rapidly developing health care infrastructure, and increase in adoption of technology in these regions.
Key players operating in the global Interleukin inhibitors market are Regeneron Pharmaceuticals, Inc. Novartis AG, Valeant Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson., Genentech, Inc. (Roche), Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., and AstraZeneca plc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.